Literature DB >> 33302300

Optimizing and Profiling Prostaglandin E2 as a Medical Countermeasure for the Hematopoietic Acute Radiation Syndrome.

Andrea M Patterson1, Tong Wu1, Hui Lin Chua1, Carol H Sampson1, Alexa Fisher1, Pratibha Singh1,2, Theresa A Guise3, Hailin Feng1, Jessica Muldoon1, Laura Wright3, P Artur Plett1, Louis M Pelus1,2, Christie M Orschell1.   

Abstract

Identification of medical countermeasures (MCM) to mitigate radiation damage and/or protect first responders is a compelling unmet medical need. The prostaglandin E2 (PGE2) analog, 16,16 dimethyl-PGE2 (dmPGE2), has shown efficacy as a radioprotectant and radiomitigator that can enhance hematopoiesis and ameliorate intestinal mucosal cell damage. In this study, we optimized the time of administration of dmPGE2 for protection and mitigation against mortality from the hematopoietic acute radiation syndrome (H-ARS) in young adult mice, evaluated its activity in pediatric and geriatric populations, and investigated potential mechanisms of action. Windows of 30-day survival efficacy for single administration of dmPGE2 were defined as within 3 h prior to and 6-30 h after total-body γ irradiation (TBI). Radioprotective and radio-mitigating efficacy was also observed in 2-year-old geriatric mice and 6-week-old pediatric mice. PGE2 receptor agonist studies suggest that signaling through EP4 is primarily responsible for the radioprotective effects. DmPGE2 administration prior to TBI attenuated the drop in red blood cells and platelets, accelerated recovery of all peripheral blood cell types, and resulted in higher hematopoietic and mesenchymal stem cells in survivor bone marrow. Multiplex analysis of bone marrow cytokines together with RNA sequencing of hematopoietic stem cells indicated a pro-hematopoiesis cytokine milieu induced by dmPGE2, with IL-6 and G-CSF strongly implicated in dmPGE2-mediated radioprotective activity. In summary, we have identified windows of administration for significant radio-mitigation and radioprotection by dmPGE2 in H-ARS, demonstrated survival efficacy in special populations, and gained insight into radioprotective mechanisms, information useful towards development of dmPGE2 as a MCM for first responders, military personnel, and civilians facing radiation threats. ©2021 by Radiation Research Society. All rights of reproduction in any form reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33302300      PMCID: PMC7929087          DOI: 10.1667/RADE-20-00181.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  53 in total

1.  The H-ARS Dose Response Relationship (DRR): Validation and Variables.

Authors:  P Artur Plett; Carol H Sampson; Hui Lin Chua; William Jackson; Sasidhar Vemula; Rajendran Sellamuthu; Alexa Fisher; Hailin Feng; Tong Wu; Thomas J MacVittie; Christie M Orschell
Journal:  Health Phys       Date:  2015-11       Impact factor: 1.316

2.  Radioprotection by 16,16 dimethyl prostaglandin E2 is equally effective in male and female mice.

Authors:  T L Walden; N K Farzaneh
Journal:  J Radiat Res       Date:  1995-03       Impact factor: 2.724

3.  In vivo modulation of murine myelopoiesis following intravenous administration of prostaglandin E2.

Authors:  P Gentile; D Byer; L M Pelus
Journal:  Blood       Date:  1983-11       Impact factor: 22.113

Review 4.  Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer?

Authors:  Mark A Hull; Stanley C W Ko; Gillian Hawcroft
Journal:  Mol Cancer Ther       Date:  2004-08       Impact factor: 6.261

5.  16, 16-dimethyl prostaglandin E2 increases survival of murine intestinal stem cells when given before photon radiation.

Authors:  W R Hanson; C Thomas
Journal:  Radiat Res       Date:  1983-11       Impact factor: 2.841

6.  Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation.

Authors:  Robert P Nelson; Muhammad Rizwan Khawaja; Susan M Perkins; Lindsey Elmore; Christen L Mumaw; Christie Orschell; Sophie Paczesny
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-10       Impact factor: 5.742

7.  Effects of combined administration of interleukin-6 and granulocyte colony-stimulating factor on recovery from radiation-induced hemopoietic aplasia.

Authors:  M L Patchen; R Fischer; T J MacVittie
Journal:  Exp Hematol       Date:  1993-02       Impact factor: 3.084

8.  PEGylated G-CSF (BBT-015), GM-CSF (BBT-007), and IL-11 (BBT-059) analogs enhance survival and hematopoietic cell recovery in a mouse model of the hematopoietic syndrome of the acute radiation syndrome.

Authors:  Paul Artur Plett; Hui Lin Chua; Carol H Sampson; Barry P Katz; Christine M Fam; Lana J Anderson; George N Cox; Christie M Orschell
Journal:  Health Phys       Date:  2014-01       Impact factor: 1.316

9.  Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization.

Authors:  G J Lieschke; D Grail; G Hodgson; D Metcalf; E Stanley; C Cheers; K J Fowler; S Basu; Y F Zhan; A R Dunn
Journal:  Blood       Date:  1994-09-15       Impact factor: 22.113

10.  Differential stem- and progenitor-cell trafficking by prostaglandin E2.

Authors:  Jonathan Hoggatt; Khalid S Mohammad; Pratibha Singh; Amber F Hoggatt; Brahmananda R Chitteti; Jennifer M Speth; Peirong Hu; Bradley A Poteat; Kayla N Stilger; Francesca Ferraro; Lev Silberstein; Frankie K Wong; Sherif S Farag; Magdalena Czader; Ginger L Milne; Richard M Breyer; Carlos H Serezani; David T Scadden; Theresa A Guise; Edward F Srour; Louis M Pelus
Journal:  Nature       Date:  2013-03-13       Impact factor: 49.962

View more
  3 in total

1.  Age and Sex Divergence in Hematopoietic Radiosensitivity in Aged Mouse Models of the Hematopoietic Acute Radiation Syndrome.

Authors:  Andrea M Patterson; Sasidhar Vemula; P Artur Plett; Carol H Sampson; Hui Lin Chua; Alexa Fisher; Tong Wu; Rajendran Sellamuthu; Hailin Feng; Barry P Katz; Colleen M DesRosiers; Louis M Pelus; George N Cox; Thomas J MacVittie; Christie M Orschell
Journal:  Radiat Res       Date:  2022-09-01       Impact factor: 3.372

2.  Prostaglandin E2 Regulates Bipotent Monocyte-Dendritic Progenitor Cell Lineage-Commitment.

Authors:  Pratibha Singh; Louis M Pelus
Journal:  Stem Cell Rev Rep       Date:  2021-06-22       Impact factor: 5.739

Review 3.  Role of prostaglandin E2 in tissue repair and regeneration.

Authors:  Hui Cheng; Haoyan Huang; Zhikun Guo; Ying Chang; Zongjin Li
Journal:  Theranostics       Date:  2021-08-13       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.